Surveillance data show Candida auris clinical cases more than doubled from 2,882 in 2022 to 6,197 in 2024, with provisional 2026 counts indicating further growth. The CDC’s urgent antimicrobial-resistance threat designation highlights ongoing spread in healthcare and long-term care settings, where colonized patients can silently seed outbreaks across facilities.